UNSPSC 51373468: Guaifenesin/hydrocodone/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373468 Guaifenesin/hydrocodone/pseudoephedrine is a Commodity code that in recent state and local practice encompasses pharmaceutical procurement across multiple product categories, including prescription medications, naloxone, and over-the-counter products supplied to county health departments and multistate cooperative purchasing alliances. State and local governments acquire these items through IFB and RFP vehicles, typically as part of broader health-service or emergency-response supply chains. Issuing bodies include county health departments and multistate cooperative purchasing alliances administered by state procurement offices. The Seminole County, Florida procurement and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP represent the two models currently visible: direct county procurement of specific pharmaceutical and medical products for community health initiatives, and cooperative purchasing agreements that establish master contracts with manufacturers for distribution through authorized wholesalers to multiple participating state and local government facilities.

Geographically, recent activity is concentrated in Florida and Minnesota, with MMCAP's scope extending to participating states including Oregon. Seminole County issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. MMCAP issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with a questions deadline of February 18, 2026, and proposals due March 26, 2026; awarded vendors would be provided to authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) by May 15, 2026, with contracts effective July 1, 2026. Both solicitations require full compliance with cGMP, FDA requirements, and federal supply-chain security standards, with pricing and delivery terms specified in the RFP and IFB documents.